During the 2022-2023 respiratory season, the bivalent COVID vaccines had an effectiveness of 54% against infection and 49% against symptomatic COVID in children and adolescents ages 5 to 17 years, a new study in JAMA showed.
In this interview, Melissa Briggs Hagen, MD, MPH, of the CDC's Coronavirus and Other Respiratory Viruses Division, discusses the data.